Open
Do investigational compounds improve blood pressure more than other treatments?
Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.00 (range 0.00–0.55)
- Trials for
- 0
- Trials against
- 1
- Inconclusive
- 1
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 45
- With posted results
- 11
- Published papers
- 0
Of 16 decided analyses: 0 favor investigational compounds, 13 find no difference, 3 favor the comparator.
Trials
- The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects With Type 2 Diabetes MellitusNCT02091362 · 3 posted results
- A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes MellitusNCT02492763 · 10 posted results
- A Phase 2 Dose Response Study of LY2484595 in Japanese SubjectsNCT01375075 · 8 posted results
- A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell FunctionNCT02443155 · 1 posted result
- Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.NCT03856047 · 2 posted results
- A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110 (R256918)NCT00672386
- A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined With Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients With Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy With a StatinNCT00261352
- A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Metformin AloneNCT00251953